Cargando…
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
PURPOSE: Despite extensive genomic and transcriptomic profiling, it remains unknown how signaling pathways are differentially activated and how tumors are differentially sensitized to certain perturbations. Here, we aim to characterize AKT signaling activity and its association with other genomic or...
Autores principales: | Shi, Zhen, Wulfkuhle, Julia, Nowicka, Malgorzata, Gallagher, Rosa I., Saura, Cristina, Nuciforo, Paolo G., Calvo, Isabel, Andersen, Jay, Passos-Coelho, José Luis, Gil-Gil, Miguel J., Bermejo, Begoña, Pratt, Debra A., Ciruelos, Eva M., Villagrasa, Patricia, Wongchenko, Matthew J., Petricoin, Emanuel F., Oliveira, Mafalda, Isakoff, Steven J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377742/ https://www.ncbi.nlm.nih.gov/pubmed/34907082 http://dx.doi.org/10.1158/1078-0432.CCR-21-2498 |
Ejemplares similares
-
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
por: Turner, Nicholas, et al.
Publicado: (2021) -
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
por: Pascual, Javier, et al.
Publicado: (2023) -
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
por: Guerrero-Zotano, Ángel, et al.
Publicado: (2023) -
Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
por: O'donnell, Jillian, et al.
Publicado: (2023) -
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)